Assenagon Asset Management S.A. Has $782,000 Position in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)

Assenagon Asset Management S.A. raised its position in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) by 70.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 444,185 shares of the biopharmaceutical company’s stock after acquiring an additional 183,396 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Marinus Pharmaceuticals were worth $782,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in MRNS. Point72 DIFC Ltd acquired a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter worth about $28,000. SG Americas Securities LLC acquired a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter worth about $34,000. AQR Capital Management LLC lifted its stake in shares of Marinus Pharmaceuticals by 70.3% during the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 12,934 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter worth about $64,000. Finally, Values First Advisors Inc. lifted its stake in shares of Marinus Pharmaceuticals by 501.8% during the 2nd quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock worth $73,000 after buying an additional 52,257 shares during the last quarter. Institutional investors and hedge funds own 98.80% of the company’s stock.

Marinus Pharmaceuticals Stock Performance

Shares of NASDAQ MRNS opened at $0.33 on Friday. Marinus Pharmaceuticals, Inc. has a 52-week low of $0.26 and a 52-week high of $11.26. The company’s 50 day moving average price is $1.44 and its 200-day moving average price is $1.39.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). The firm had revenue of $8.06 million during the quarter, compared to analyst estimates of $9.05 million. Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. During the same quarter last year, the firm posted ($0.61) EPS. On average, analysts predict that Marinus Pharmaceuticals, Inc. will post -1.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. StockNews.com assumed coverage on shares of Marinus Pharmaceuticals in a research note on Saturday. They set a “hold” rating for the company. Jefferies Financial Group reaffirmed a “hold” rating and set a $0.50 price target (down from $5.00) on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. HC Wainwright reissued a “neutral” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Cantor Fitzgerald decreased their target price on shares of Marinus Pharmaceuticals from $13.00 to $4.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Finally, EF Hutton Acquisition Co. I raised shares of Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. Nine investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $6.07.

Marinus Pharmaceuticals Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.